Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-99
SponsorColumbia University
About this trial
The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- Letermovir
- Valganciclovir
Treatment groups
150 Participants
are divided into 3 treatment groupsLocations
2Columbia University/NYP Milstein Hospital10032, New YorkNew York, United States
NYP-Weill Cornell10021, New YorkNew York, United States
Sponsors and collaborators
Columbia University
Lead sponsor
Cornell University
Collaborator
Source ClinicalTrials.gov